Extrapolating theoretical efficacy of inactivated influenza A/H5N1 virus vaccine from human immunogenicity studies.

Influenza A virus subtype H5N1 has been a public health concern for almost 20years due to its potential ability to become transmissible among humans. Phase I and II clinical trials have assessed safety, reactogenicity and immunogenicity of inactivated influenza A/H5N1 virus vaccines. A shortage of vaccine is likely to occur during the first months of a pandemic. Hence, determining whether to give one dose to more people or two doses to fewer people to best protect the population is essential. We use hemagglutination-inhibition antibody titers as an immune correlate for avian influenza vaccines. Using an established relationship to obtain a theoretical vaccine efficacy from immunogenicity data from thirteen arms of six phase I and phase II clinical trials of inactivated influenza A/H5N1 virus vaccines, we assessed: (1) the proportion of theoretical vaccine efficacy achieved after a single dose (defined as primary response level), and (2) whether theoretical efficacy increases after a second dose, with and without adjuvant. Participants receiving vaccine with AS03 adjuvant had higher primary response levels (range: 0.48-0.57) compared to participants receiving vaccine with MF59 adjuvant (range: 0.32-0.47), with no observed trends in primary response levels by antigen dosage. After the first and second doses, vaccine with AS03 at dosage levels 3.75, 7.5 and 15mcg had the highest estimated theoretical vaccine efficacy: Dose (1) 45% (95% CI: 36-57%), 53% (95% CI: 42-63%) and 55% (95% CI: 44-64%), respectively and Dose (2) 93% (95% CI: 89-96%), 97% (95% CI: 95-98%) and 97% (95% CI: 96-100%), respectively. On average, the estimated theoretical vaccine efficacy of lower dose adjuvanted vaccines (AS03 and MF59) was 17% higher than that of higher dose unadjuvanted vaccines, suggesting that including an adjuvant is dose-sparing. These data indicate adjuvanted inactivated influenza A/H5N1 virus vaccine produces high theoretical efficacy after two doses to protect individuals against a potential avian influenza pandemic.

[1]  W. Keitel,et al.  Safety, Reactogenicity, and Immunogenicity of Inactivated Monovalent Influenza A(H5N1) Virus Vaccine Administered With or Without AS03 Adjuvant , 2014, Open forum infectious diseases.

[2]  D. Bernstein,et al.  Effects of adjuvants on the safety and immunogenicity of an avian influenza H5N1 vaccine in adults. , 2008, The Journal of infectious diseases.

[3]  Ira M Longini,et al.  Critical immune and vaccination thresholds for determining multiple influenza epidemic waves. , 2012, Epidemics.

[4]  Mark Wolff,et al.  Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. , 2006, The New England journal of medicine.

[5]  D. Cummings,et al.  Strategies for containing an emerging influenza pandemic in Southeast Asia , 2005, Nature.

[6]  I. Longini,et al.  The critical vaccination fraction for heterogeneous epidemic models. , 2003, Mathematical biosciences.

[7]  M. Elizabeth Halloran,et al.  Detecting Human-to-Human Transmission of Avian Influenza A (H5N1) , 2007, Emerging Infectious Diseases.

[8]  W. Carr,et al.  Half- vs full-dose trivalent inactivated influenza vaccine (2004-2005): age, dose, and sex effects on immune responses. , 2008, Archives of internal medicine.

[9]  S. Unal,et al.  A phase II, randomised clinical trial to demonstrate the non-inferiority of low-dose MF59-adjuvanted pre-pandemic A/H5N1 influenza vaccine in adult and elderly subjects. , 2012, Journal of preventive medicine and hygiene.

[10]  E. Shin,et al.  Evaluation of heterosubtypic cross-protection against highly pathogenic H5N1 by active infection with human seasonal influenza A virus or trivalent inactivated vaccine immunization in ferret models. , 2014, The Journal of general virology.

[11]  René Ecochard,et al.  Relationship between haemagglutination-inhibiting antibody titres and clinical protection against influenza: development and application of a bayesian random-effects model , 2010, BMC medical research methodology.

[12]  J. Piercy,et al.  Immunogenicity and protective efficacy of influenza vaccination. , 2004, Virus research.

[13]  C. Macken,et al.  Mitigation strategies for pandemic influenza in the United States. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[14]  G. Leroux-Roels,et al.  Priming with AS03 A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: an open non-randomised extension of a double-blind randomised primary study. , 2010, Vaccine.

[15]  J. Belmont,et al.  Antibody correlates and predictors of immunity to naturally occurring influenza in humans and the importance of antibody to the neuraminidase. , 2013, The Journal of infectious diseases.

[16]  M. Knuf,et al.  Single dose vaccination with AS03-adjuvanted H5N1 vaccines in a randomized trial induces strong and broad immune responsiveness to booster vaccination in adults. , 2009, Vaccine.

[17]  Mark Wolff,et al.  Evaluation of a single dose of half strength inactivated influenza vaccine in healthy adults. , 2002, Vaccine.

[18]  M. Mulligan,et al.  Safety and immunogenicity of influenza A H5 subunit vaccines: effect of vaccine schedule and antigenic variant. , 2011, The Journal of infectious diseases.

[19]  B. Cowling,et al.  Association between antibody titers and protection against influenza virus infection within households. , 2014, The Journal of infectious diseases.

[20]  A. Falsey,et al.  Half-dose influenza vaccine: stretching the supply or wasting it? , 2008, Archives of internal medicine.

[21]  M. Halloran,et al.  One versus two doses: What is the best use of vaccine in an influenza pandemic? , 2015, Epidemics.

[22]  Y. Ghendon.  The immune response to influenza vaccines. , 1990, Acta virologica.

[23]  A. J. Hall.  Infectious diseases of humans: R. M. Anderson & R. M. May. Oxford etc.: Oxford University Press, 1991. viii + 757 pp. Price £50. ISBN 0-19-854599-1 , 1992 .

[24]  C. Woods,et al.  Immunogenicity of avian influenza A/Anhui/01/2005(H5N1) vaccine with MF59 adjuvant: a randomized clinical trial. , 2014, JAMA.

[25]  M Elizabeth Halloran,et al.  Planning for the control of pandemic influenza A (H1N1) in Los Angeles County and the United States. , 2011, American journal of epidemiology.

[26]  J P Fox,et al.  Influenzavirus infections in Seattle families, 1975-1979. II. Pattern of infection in invaded households and relation of age and prior antibody to occurrence of infection and related illness. , 1982, American journal of epidemiology.

[27]  G. Leroux-Roels.  Prepandemic H5N1 influenza vaccine adjuvanted with AS03: a review of the pre-clinical and clinical data , 2009, Expert opinion on biological therapy.

[28]  A. Osterhaus,et al.  Haemagglutination-inhibiting antibody to influenza virus. , 2003, Developments in biologicals.

[29]  J. Stockman.  Dose Sparing With Intradermal Injection of Influenza Vaccine , 2006 .

[30]  C. Raina MacIntyre,et al.  Optimal Dosing and Dynamic Distribution of Vaccines in an Influenza Pandemic , 2009, American journal of epidemiology.

[31]  M. Sung,et al.  Evaluation of the efficacy of a pre-pandemic H5N1 vaccine (MG1109) in mouse and ferret models , 2012, Journal of Microbiology.

[32]  W. Keitel,et al.  Dose ranging of adjuvant and antigen in a cell culture H5N1 influenza vaccine: safety and immunogenicity of a phase 1/2 clinical trial. , 2010, Vaccine.

[33]  T. Rebmann,et al.  Vaccination against influenza: role and limitations in pandemic intervention plans , 2012, Expert review of vaccines.

[34]  Steven Riley,et al.  Optimizing the Dose of Pre-Pandemic Influenza Vaccines to Reduce the Infection Attack Rate , 2007, PLoS medicine.

[35]  Gail E. Potter,et al.  The Transmissibility and Control of Pandemic Influenza A (H1N1) Virus , 2009, Science.

[36]  Hualan Chen,et al.  A subunit vaccine candidate derived from a classic H5N1 avian influenza virus in China protects fowls and BALB/c mice from lethal challenge. , 2013, Vaccine.

[37]  A. Nizam,et al.  Containing Pandemic Influenza at the Source , 2005, Science.

[38]  D. Bernstein,et al.  Serological responses to an avian influenza A/H7N9 vaccine mixed at the point-of-use with MF59 adjuvant: a randomized clinical trial. , 2014, JAMA.

[39]  A. S. Beare,et al.  The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses , 1972, Epidemiology and Infection.

[40]  D. Bernstein,et al.  Point-of-Use Mixing of Influenza H5N1 Vaccine and MF59 Adjuvant for Pandemic Vaccination Preparedness: Antibody Responses and Safety. A Phase 1 Clinical Trial , 2014, Open forum infectious diseases.

[41]  S. El-Kamary,et al.  Safety and Immunogenicity of a Single Low Dose or High Dose of Clade 2 Influenza A(H5N1) Inactivated Vaccine in Adults Previously Primed With Clade 1 Influenza A(H5N1) Vaccine. , 2015, The Journal of infectious diseases.